PHARMA MAR SA

Pharma Mar SA has enrolled 705 patients in its phase III LAGOON trial for Zepzelca® (lurbinectedin) in small cell lung cancer treatment, with results expected by early 2026. The trial focuses on overall and progression-free survival, advancing cancer therapy research.